Evidence map›Paper›PMID 29588403›Full record

ArticlemBio2018

Exogenous Stimulation of Type I Interferon Protects Mice with Chronic Granulomatous Disease from Aspergillosis through Early Recruitment of Host-Protective Neutrophils into the Lung.

Seyedmojtaba Seyedmousavi, Michael J Davis, Janyce A Sugui, Tzvia Pinkhasov, Shannon Moyer, Andres M Salazar, Yun C Chang, Kyung J Kwon-Chung

Open access · goldAbstract read
In one paragraph

Article in mBio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Virulence ofVirulence · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Antimicrobial agents and chemotherapy · 2021
    Article
  7. Review
  8. Sensing the threat posed by Aspergillus infection.Current opinion in microbiology · 2020
    Review
  9. Article
  10. Article
  11. Aspergillus fumigatus and Aspergillosis in 2019.Clinical microbiology reviews · 2019
    Review
  12. Review
  13. Article
  14. Efficacy of Olorofim (F901318) againstAntimicrobial agents and chemotherapy · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Seyedmojtaba Seyedmousavi *Molecular Microbiology Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.ORCID 0000-0002-6194-7447
Michael J Davis *Molecular Microbiology Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
Janyce A Sugui *Molecular Microbiology Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
Tzvia PinkhasovMolecular Microbiology Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
Shannon MoyerMolecular Microbiology Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
Andres M SalazarOncovir Inc., Washington, DC, USA.
Yun C ChangMolecular Microbiology Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
Kyung J Kwon-ChungMolecular Microbiology Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA June_kwon-chung@nih.gov.
National Institutes of Health · USOncovir (United States) · US

Funding

Basic Studies On Aspergillus SpeciesZIAAI000657 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KWON-CHUNG, KYUNG · 2009 to 2020
$4.3M
6 · The paper itself

Abstract

Invasive aspergillosis (IA) remains the primary cause of morbidity and mortality in chronic granulomatous disease (CGD) patients, often due to infection by

Indexed as

AnimalsAntifungal AgentsAspergillosisAspergillusFlow CytometryGranulomatous Disease, ChronicInterferon Type ILungMaleMiceMice, KnockoutNeutrophilsAntifungal AgentsInterferon Type IAspergillus fumigatusAspergillus nidulansAspergillus tannerichronic granulomatous disease (CGD)conidianeutrophilsphagocyte recruitmentpoly(I:C) (PICLC)type I IFN

Identifiers

PMID29588403
PMCPMC5874922
OpenAlexW2791402554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.